Healthcare Contract Sales Organizations (CSOs) Market Size, Share, and Trends 2024 to 2034

The global healthcare contract sales organizations (CSOs) market size is calculated at USD 15.92 billion in 2024, grew to USD 17.23 billion in 2025, and is predicted to hit around USD 35.02 billion by 2034, poised to grow at a CAGR of 8.2% between 2024 and 2034. The North America healthcare contract sales organizations (CSOs) market size accounted for USD 6.69 billion in 2024 and is anticipated to grow at the fastest CAGR of 8.32% during the forecast year.

  • Last Updated : October 2024
  • Report Code : 3358
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Healthcare Contract Sales Organizations (CSOs) Market 

5.1. COVID-19 Landscape: Healthcare Contract Sales Organizations (CSOs) Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Healthcare Contract Sales Organizations (CSOs) Market, By Service

8.1. Healthcare Contract Sales Organizations (CSOs) Market, by Service, 2024-2034

8.1.1. Personal Promotion

8.1.1.1. Market Revenue and Forecast (2021-2034)

8.1.2. Non-Personal Promotion

8.1.2.1. Market Revenue and Forecast (2021-2034)

Chapter 9. Global Healthcare Contract Sales Organizations (CSOs) Market, By End-use

9.1. Healthcare Contract Sales Organizations (CSOs) Market, by End-use, 2024-2034

9.1.1. Pharmaceutical Companies

9.1.1.1. Market Revenue and Forecast (2021-2034)

9.1.2. Biopharmaceutical Companies

9.1.2.1. Market Revenue and Forecast (2021-2034)

9.1.3. Medical device Companies

9.1.3.1. Market Revenue and Forecast (2021-2034)

Chapter 10. Global Healthcare Contract Sales Organizations (CSOs) Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Service (2021-2034)

10.1.2. Market Revenue and Forecast, by End-use (2021-2034)

10.1.3. U.S.

10.1.3.1. Market Revenue and Forecast, by Service (2021-2034)

10.1.3.2. Market Revenue and Forecast, by End-use (2021-2034)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Forecast, by Service (2021-2034)

10.1.4.2. Market Revenue and Forecast, by End-use (2021-2034)

10.2. Europe

10.2.1. Market Revenue and Forecast, by Service (2021-2034)

10.2.2. Market Revenue and Forecast, by End-use (2021-2034)

10.2.3. UK

10.2.3.1. Market Revenue and Forecast, by Service (2021-2034)

10.2.3.2. Market Revenue and Forecast, by End-use (2021-2034)

10.2.4. Germany

10.2.4.1. Market Revenue and Forecast, by Service (2021-2034)

10.2.4.2. Market Revenue and Forecast, by End-use (2021-2034)

10.2.5. France

10.2.5.1. Market Revenue and Forecast, by Service (2021-2034)

10.2.5.2. Market Revenue and Forecast, by End-use (2021-2034)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Forecast, by Service (2021-2034)

10.2.6.2. Market Revenue and Forecast, by End-use (2021-2034)

10.3. APAC

10.3.1. Market Revenue and Forecast, by Service (2021-2034)

10.3.2. Market Revenue and Forecast, by End-use (2021-2034)

10.3.3. India

10.3.3.1. Market Revenue and Forecast, by Service (2021-2034)

10.3.3.2. Market Revenue and Forecast, by End-use (2021-2034)

10.3.4. China

10.3.4.1. Market Revenue and Forecast, by Service (2021-2034)

10.3.4.2. Market Revenue and Forecast, by End-use (2021-2034)

10.3.5. Japan

10.3.5.1. Market Revenue and Forecast, by Service (2021-2034)

10.3.5.2. Market Revenue and Forecast, by End-use (2021-2034)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Forecast, by Service (2021-2034)

10.3.6.2. Market Revenue and Forecast, by End-use (2021-2034)

10.4. MEA

10.4.1. Market Revenue and Forecast, by Service (2021-2034)

10.4.2. Market Revenue and Forecast, by End-use (2021-2034)

10.4.3. GCC

10.4.3.1. Market Revenue and Forecast, by Service (2021-2034)

10.4.3.2. Market Revenue and Forecast, by End-use (2021-2034)

10.4.4. North Africa

10.4.4.1. Market Revenue and Forecast, by Service (2021-2034)

10.4.4.2. Market Revenue and Forecast, by End-use (2021-2034)

10.4.5. South Africa

10.4.5.1. Market Revenue and Forecast, by Service (2021-2034)

10.4.5.2. Market Revenue and Forecast, by End-use (2021-2034)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Forecast, by Service (2021-2034)

10.4.6.2. Market Revenue and Forecast, by End-use (2021-2034)

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Service (2021-2034)

10.5.2. Market Revenue and Forecast, by End-use (2021-2034)

10.5.3. Brazil

10.5.3.1. Market Revenue and Forecast, by Service (2021-2034)

10.5.3.2. Market Revenue and Forecast, by End-use (2021-2034)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Forecast, by Service (2021-2034)

10.5.4.2. Market Revenue and Forecast, by End-use (2021-2034)

Chapter 11. Company Profiles

11.1. Ashfield Healthcare Communications

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Publicis Health

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. IQVIA

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Syneos Health

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. M3 USA

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. QuintilesIMS

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. C3i Solutions

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. InVentiv Health

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. PDI, Inc.

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. Alphanumeric Systems, Inc.

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client